CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku od 18 do 70 lat
- •Potwierdzony histologicznie nowotwór piersi z przerzutami do węzłów chłonnych lub bez
- •Ukończona chemioterapia przed operacją i sama operacja (w ciągu 4 lat od zabiegu)
- •Otrzymana chemioterapia przed operacją
- •Ogólny stan zdrowia pozwalający na aktywność codzienną
✗ Disqualifies
- •Przerzuty nowotworu do innych organów
- •Ciąża lub karmienie piersią
- •Nieopanowana infekcja w miejscu zabiegu lub infekcja ogólna
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- February 3, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.